News

Lung Airway Chip Accurately Models Cystic Fibrosis

For the first time, many features of cystic fibrosis (CF) were modeled accurately in a human Lung Airway Chip lined with cells from CF patients, which included enhanced mucus secretion, inflammation, and microbial infections, a study has shown. This “organ-on-a-chip model” of the disease may support the rapid development…

P. Aeruginosa Metabolites May Enable Better Patient Management

Molecules produced by the environmental bacteria Pseudomonas aeruginosa, called alkyl-quinolones derivatives — which regulate bacterial gene activity and act in cell-to-cell communication — may be useful markers for better management of patients with cystic fibrosis (CF), a study suggests. These derivatives also may enable a more clear definition…

CHMP Favors Kaftrio to Treat Children in EU Starting at Age 6

A branch of the European Medicines Agency (EMA) has recommended expanding Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to include children with cystic fibrosis (CF) as young as age 6 who have at least one F508del mutation. The recommendation, from the EMA’s Committee for Medicinal Products for Human Use (CHMP),…

Elexacaftor Also Works as CFTR Potentiator, Study Says

Elexacaftor (VX-445), a next-generation CFTR corrector that is part of the triple-combination therapy Trikafta, is also a potentiator, a study reports. Results further showed that in combination with ivacaftor, sold as Kalydeco and also a potentiator, elexacaftor boosts ion flow across CFTR, the…